摘要
目的观察前列地尔治疗糖尿病肾病的临床疗效，并探讨其肾脏保护作用的机制。方法对100例糖尿病肾病患者随机分为治疗组50例及对照组50例，对照组按糖尿病常规治疗，治疗组在对照组治疗的基础上加用前列地尔治疗，10μg／d，疗程12d。观察两组治疗前后尿蛋白变化及药物不良反应发生情况。结果治疗组尿蛋白阴转率为94％，与对照组（40％）比较，差异有统计学意义（P〈0．05）。结论前列地尔能明显减少糖尿病肾病患者的尿蛋白排泄量，是治疗糖尿病肾病安全、有效的药物。
Objective To observe the effectiveness of alprostadil in treatment of diabetic nephropathy and the mechanism of the renal protection of the drug. Methods One hundred patients with diabetic nephrepathy due to diabetes mellitus were randomly divided into 2 groups,50 in treatment group, and 50 as controls, alprostadil was used intravenously in the Treatment Group for 12 day while routine management of diabetes such as food intake control, physical exercises and oral drugs or injection of insulin was conducted in both of the 2 groups. Urinary albumin were employed for evaluation as well as the side-effects. Results By the end of the trial, urinary albumin was decreased significantly compared with those before intravenous alprostadil treatment or with those in the control group （P 〈 0. 05）. Conclusion Urinary albumin was decreased significantly after intravenous alprostadil. Therefore, it is a safe and effective drug in the treatment of diabetic nephropathy.
出处
《中国基层医药》
CAS
2008年第10期1666-1667,共2页
Chinese Journal of Primary Medicine and Pharmacy
